alefacept, efalizumab, etanercept, and infliximab). In a recent Japanese Society for Psoriasis Research analysis of 28,628 cases, herbal medicines (14.5%) ranked highest among systemic therapies used.
certolizumab pegol or tocilizumab within 12 weeks of randomisation or alefacept or ustekinumab within 24 weeks of randomisation; or (6) had prior treatment with apremilast. Topical therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback